- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04782440
The Effect of Telerehabilitation of Patients With Duchenne Muscular Dystrophy
March 2, 2021 updated by: Marmara University
The aim of this study is to investigate the effect of a telerehabilitation approach to patients with Duchenne Muscular Dystrophy and evaluate patients' motor function, parents' anxiety and depression levels before and after the intervention
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Patients with Duchenne muscular dystrophy
Exclusion Criteria:
- Patients without the ability of independent ambulation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Telerehabilitation
|
Patients will receive telerehabilitation sessions that include strengthening, stretching and range of motion exercises
|
|
Active Comparator: Home exercise
|
Patients will be given a home-based exercise program without telerehabilitation supervision
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Quick motor function test
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 1, 2021
Primary Completion (Anticipated)
August 1, 2021
Study Completion (Anticipated)
September 1, 2021
Study Registration Dates
First Submitted
March 2, 2021
First Submitted That Met QC Criteria
March 2, 2021
First Posted (Actual)
March 4, 2021
Study Record Updates
Last Update Posted (Actual)
March 4, 2021
Last Update Submitted That Met QC Criteria
March 2, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1455
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Dyne TherapeuticsRecruitingMuscular Dystrophies | Muscular Dystrophy, Duchenne | Duchenne Muscular Dystrophy (DMD) | Muscular Dystrophy, Duchenne and Becker Types | Genetic Disease, X-Linked | Genetic Disease, Inborn | DMD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Muscular Dystrophy (DMD) | Muscular Dystrophies... and other conditionsUnited States
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
PepGen IncWithdrawnDuchenne Muscular Dystrophy (DMD)United Kingdom
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
Clinical Trials on Telerehabilitaton
-
Istanbul University - Cerrahpasa (IUC)The Scientific and Technological Research Council of TurkeyRecruitingStroke | Multiple Sclerosis | Parkinson DiseaseTurkey